AbCellera Biologics Inc. Repayments of Long-Term Debt
AbCellera Biologics Inc. (ABCL) reported Repayments of Long-Term Debt of $1.82 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-25.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebt · last filed 2022-02-25
- AbCellera Biologics Inc. repayments of long-term debt for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- AbCellera Biologics Inc. repayments of long-term debt for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- AbCellera Biologics Inc. repayments of long-term debt for the quarter ending 2021-06-30 was $107.00K.
- AbCellera Biologics Inc. repayments of long-term debt for the quarter ending 2021-03-31 was $1.72M, a 15.59% decline year-over-year.
- AbCellera Biologics Inc. repayments of long-term debt for fiscal 2021 was $1.82M, a 90.86% decline from fiscal 2020.
- AbCellera Biologics Inc. repayments of long-term debt for fiscal 2020 was $19.94M, a 4897.99% increase from fiscal 2019.
- AbCellera Biologics Inc. repayments of long-term debt for fiscal 2019 was $399.00K.
| Period end | Repayments of Long-term Debt 3 month | Repayments of Long-term Debt 6 month | Repayments of Long-term Debt 9 month | Repayments of Long-term Debt 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $0.00 derived: sum of 2 quarters · filed 2022-02-25 | $107.00K derived: sum of 3 quarters · filed 2022-02-25 | $1.82M 10-K · filed 2022-02-25 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $107.00K derived: sum of 2 quarters · filed 2021-11-10 | $1.82M 10-Q · filed 2021-11-10 | $4.79M derived: sum of 4 quarters · filed 2022-02-25 |
| 2021-06-30 | $107.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $1.82M 10-Q · filed 2021-08-13 | $4.79M derived: sum of 3 quarters · filed 2022-02-25 | $19.79M derived: sum of 4 quarters · filed 2022-02-25 |
| 2021-03-31 | $1.72M 10-Q · filed 2021-05-14 | $4.69M derived: sum of 2 quarters · filed 2022-02-25 | $19.69M derived: sum of 3 quarters · filed 2022-02-25 | $19.63M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-12-31 | $2.97M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $17.97M derived: sum of 2 quarters · filed 2022-02-25 | $17.91M derived: sum of 3 quarters · filed 2022-02-25 | $19.94M 10-K · filed 2022-02-25 |
| 2020-09-30 | $15.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $14.94M derived: sum of 2 quarters · filed 2021-11-10 | $16.97M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$62.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $1.97M 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $2.03M 10-Q · filed 2021-05-14 | |||
| 2019-12-31 | $399.00K 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |